evaluate novo nordisk on glp-1 agonists Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say Glucometabolic outcomes of GLP-1 receptor

GLP-1 Drugs for Obesity and Weight Loss What is a GLP-1

A new survey report from the International Foundation of Employee Benefit Plans reveals results from a group of Canadian employers regarding considerations and coverage for glucagon-like peptide-1 (GLP-1) drugs, which have historically been used to treat diabetes and are increasingly being used to treat obesity

As a secondary end-point, a direct comparison with liraglutide (up to 1.8 mg) was made

Vomiting, diarrhea and constipation occur less frequently but still affect notable numbers of patients

Important warnings include thyroid tumor risk, pancreatitis, gallbladder disease, dehydration-related kidney injury, and hypoglycemia when used with insulin or sulfonylureas

This study adheres to the reporting guidelines outlined within the 'Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement